Uncategorized
Roclatan achieves primary efficacy endpoint in phase 3 Mercury 1 trial
Roclatan, a fixed-dose prostaglandin combination eye drop, reduced IOP more than each of its individual components at all time points measured, thus meeting its 90-day primary efficacy endpoint in the Mercury 1 trial, Aerie Pharmaceuticals announced.As part of the 12-month phase 3 trial, Roclatan (netarsudil 0.02%, latanoprost ophthalmic solution 0.005%) was dosed daily, and IOP reduction was compared with daily dosing of each of its components in patients with maximum baseline IOP between 20 mm Hg and 36 mm Hg. Roclatan reduced IOP between 1.3 mm Hg and 2.5 mm (Read more...)